Pharmexcil urges a review of a new rule for drug exports in India, which requires a product registration certificate from the importing country or Indian regulator approval. This could strain India's pharmaceutical export sector and potentially lead to illegal dealings. The new rule's complexity and challenges could burden exporters, stifle innovation, and inadvertently harm India's pharma industry.
